Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 9;1(1):24-9.
doi: 10.3109/21556660.2012.655816. eCollection 2012.

Acid reducing agents to neonates - lack of evidence and guidelines

Stina Paulsson  1 , Staffan Eksborg  2 , Åsa Andersson  3 , Per Nydert  3 , Lena Grahnquist  4
Affiliations

Acid reducing agents to neonates - lack of evidence and guidelines

Stina Paulsson et al. J Drug Assess. .

Abstract

Objective: The aim of this retrospective study was to investigate the clinical practice, i.e. the frequency of use and the treatment strategies, for acid reducing drugs to neonates in a Swedish hospital.

Methods: Retrospective reviews of charts and interviews with nurses at the neonatal wards of Karolinska University Hospital were performed to identify difficulties that might occur with drug administration. All patients admitted over a 2-month period were included. Main outcome measure were the number of patients treated with acid reducing drugs and the dosages.

Results: Nine out of 215 patients (4.2%) received an acid reducing drug. Patients treated with acid reducing drugs had significantly lower birth weight, lower gestational age and longer duration of hospitalization. Eight of the patients were treated with omeprazole. One of these patients started treatment with omeprazole but continued later on with ranitidine. One patient was exclusively treated with ranitidine. The doses of omeprazole (intravenous or oral administration) were within the range 0.16-1.26 mg/kg/day.

Conclusions: A wide variation in treatment regimens of acid reducing drugs is given to newborn infants. The percentage of treated children was much lower than earlier reports from the US and UK. No conclusions can be drawn as to whether the doses and dosing intervals used give sufficient acid suppression, since the effect of the therapy was not recorded. The present study is only retrospective and data are not truly comparable with other studies. Further studies are therefore warranted to evaluate effective doses and pharmacokinetics of acid reducing drugs in newborn infants.

Keywords: Histamine2 receptor antagonists; Neonates; Pharmaceutical preparations; Proton pump inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Birth weight in patients treated with acid reducing drugs versus non-treated patients. The median values are expressed by the solid lines.
Figure 2.
Figure 2.
Gestational age in patients treated with acid reducing drugs versus non-treated patients. The median values are expressed by the solid lines.
Figure 3.
Figure 3.
Days of hospitalization in patients treated with acid reducing drugs versus non-treated patients. The median values are expressed by the solid lines.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. James LP, Farrar HC, Palmer K, et al. Gastrointestinal drugs. In Yaffe SJ, Aranda JV. Neonatal and Paediatric Pharmacology- Therapeutics Principles in Practice, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2005
    1. Grahnquist L, Ruuska T, Finkel Y. Early development of human gastric H, K- adenosine triphosphatase. J Pediar Gastroenterol Nutr 2000;30:533-7 - PubMed
    1. Kelly EJ, Brownlee KG, Newell SJ. Gastric secretory function in the developing human stomach. Early Hum Dev 1992;31:163-6 - PubMed
    1. Kaijser M, Akre O, Cnattingius S, et al. Preterm birth, low birth weight, and risk for esophageal adenocarcinoma. Gastroenterology 2005;128:607-9 - PubMed
    1. Akre O, Forssell L, Kaijser M, et al. Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2006;15:867-71 - PubMed

LinkOut - more resources